# Gentronix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gentronix

- Industry: Biotechnology
- Headquarters: Cheshire, UK
- Website: www.gentronix.co.uk/
- Latest round: Seed (Jun 1, 1999)
- Investors on record: 2

## About

Based in Cheshire, UK, and founded in 1999, Gentronix Limited is a biotechnology company that creates screening tests to detect genetic toxins early in the medicine discovery process. In September 2024, Scantox A/S, a portfolio company of Impilo, acquired Gentronix Limited from Manchester Technology Fund, YFM Equity Partners, The University of Manchester Intellectual Property, etc. As of October 2024, Matt Tate is the Chief Executive Officer (CEO) of the company.

Gentronix is a specialized research organization that provides services to predict how chemicals can be harmful, especially in areas like genetic safety and skin reactions. The company offers services, such as testing for genetic toxicity and skin safety, helping clients prove that the chemicals are safe and observe with regulations. Gentronix focuses on maintaining strong scientific standards and uses advanced methods to identify potential hazards early in product development.

## Funding rounds

- Seed, Jun 1, 1999 — YFM Equity Partners, Manchester Technology Fund

## Investors

- YFM Equity Partners (https://capitalatlas.ai/funds/yfm-equity-partners) — Seed
- Manchester Technology Fund — Seed